Endoscopic correction of complex cases of vesicoureteral reflux utilizing Vantris as a new non-biodegradable

Boris Chertin1, Wael Abu Arafeh, Stanislav Kocherov

  • 1Department of Pediatric Urology, Shaare Zedek Medical Center, Faculty of Medical Science, Hebrew University, P.O.B 3235, 91031, Jerusalem, Israel, boris.chertin@gmail.com.

Insights

Vantris injection effectively treated complex vesicoureteral reflux (VUR) in children, achieving high success rates and normal kidney appearance post-procedure. This new non-biodegradable substance shows promise for VUR resolution.

Area of Science:

  • Pediatric Urology
  • Minimally Invasive Surgery
  • Biomaterials

Background:

  • Vesicoureteral reflux (VUR) in children, especially complex cases, presents significant management challenges.
  • Endoscopic correction is a common treatment modality, but efficacy in intricate VUR anatomies requires evaluation.
  • Novel tissue-augmenting substances are needed to improve outcomes in challenging VUR cases.

Purpose of the Study:

  • To prospectively assess the efficacy of Vantris, a new non-biodegradable tissue-augmenting substance, for endoscopic correction of complex VUR in pediatric patients.
  • To evaluate the success rate and safety profile of Vantris in a cohort of children with diverse and complicated VUR presentations.

Main Methods:

  • A prospective study involving 37 children with complex VUR undergoing endoscopic correction with Vantris over four years.
  • Treatment encompassed various complex VUR etiologies including persistent reflux, duplication, diverticulum, poorly functioning kidneys, ureterocele, stump reflux, prune belly syndrome, and urogenital sinus.
  • VUR grading ranged from Grade I to V, with a total of 38 renal refluxing units treated.

Main Results:

  • Successful reflux correction was achieved in 89.4% of renal refluxing units (RRU) after a single Vantris injection and in an additional 5.3% after a second injection.
  • No VUR recurrence was observed during follow-up.
  • Voiding cystourethrogram (VCUG) and ultrasound (US) demonstrated successful outcomes, with US showing normal kidney appearance in all patients.

Conclusions:

  • Vantris injection demonstrates a high success rate for reflux resolution in complex pediatric VUR cases.
  • The non-biodegradable nature of Vantris appears to provide durable correction.
  • Vantris represents a promising new option for managing challenging VUR anatomies in children.
Abstract